Key result
The Pro12Ala genotype was associated with a significantly higher response rate to rosiglitazone compared to the Pro12Pro genotype in patients with type 2 diabetes (86.67% vs 43.72%, P=0.002).
Why the study?
Does the Pro12Ala polymorphism of the PPARgamma2 gene affect the glycemic response to rosiglitazone in patients with type 2 diabetes mellitus?
Population
198 patients with type 2 diabetes mellitus
Comparison
Rosiglitazone 4 mg/d for 12 weeks without a… vs Patients with the Pro12Pro genotype compared to…
Design
Cohort
Follow-up
12 weeks
Authors
Loading...
Pro12Ala carriers showed greater HbA1c reduction on rosiglitazone; leaves open whether genotyping should guide T2DM therapy.
Observational (n=198)
Does the Pro12Ala polymorphism of the PPARgamma2 gene affect the glycemic response to rosiglitazone in patients with type 2 diabetes mellitus?
Absolute Event Rate: 86.67% vs 43.72%
p-value: p=.002
Patients with type 2 diabetes carrying the Pro12Ala genotype in the PPARgamma2 gene exhibit a significantly better glycemic response to rosiglitazone compared to those with the Pro12Pro genotype.
Kang et al. (2005) conducted an observational in type 2 diabetes mellitus (n=198). Pro12Ala genotype vs. Pro12Pro genotype was evaluated on Response rate to rosiglitazone treatment (p=.002). The Pro12Ala genotype was associated with a significantly higher response rate to rosiglitazone compared to the Pro12Pro genotype in patients with type 2 diabetes (86.67% vs 43.72%, P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: